Dana L. Johnson, Upper Black Eddy US
Dana L. Johnson, Upper Black Eddy, PA US
Patent application number | Description | Published |
---|---|---|
20080227821 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS ANTI-MITOTIC TUBULIN POLYMERIZATION INHIBITORS - The invention is directed to compounds having the following structures: | 09-18-2008 |
20090098181 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS - The invention is directed to triazolopyridazine compounds of Formula I: | 04-16-2009 |
20090119019 | Small Molecule Mimetics of Erythropoietin - The invention features computer-assisted methods for identifying molecules which will bind to the EPO receptor and act as an erythropoietin (EPO) mimetic. Preferred EPO mimetics identified using the method of the invention act as agonists of the EPO receptor in one or more in vitro or in vivo biological assays of EPO activity. | 05-07-2009 |
20090197913 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR - The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I′: | 08-06-2009 |
20100144695 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 - The present invention comprises compounds of Formula (I). | 06-10-2010 |
20100250600 | Small Molecule Mimetics of Erythropoietin - The invention features computer-assisted methods for identifying molecules which will bind to the EPO receptor and act as an erythropoietin (EPO) mimetic. Preferred EPO mimetics identified using the method of the invention act as agonists of the EPO receptor in one or more in vitro or in vivo biological assays of EPO activity. | 09-30-2010 |
20100267689 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 - The present invention comprises compounds of Formula (I): | 10-21-2010 |
20120040960 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 - The present invention comprises compounds of Formula (I): | 02-16-2012 |